Suggested approaches are described, using up-to-date literature, to aid clinicians in navigating the integration of newer targeted agents with hypofractionated palliative and/or ablative metastatic RT. Further prospective studies are required.
				
					
						
							
						
					
					pubmed.ncbi.nlm.nih.gov